John Glasspool

Chief Executive Officer

2024

Member of the Board Emerging Companies Section Governing Board

2022

Venture Partner

2018

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Board Member

2019

Relmada (Nasdaq: $RLMD) is a clinical-stage company developing novel therapies for the treatment of CNS diseases.

Senior Advisor

2016

Advisor/Contributor on key initiatives, including financing/reimbursement models, policy recommendations for durable therapies, and Efficacy to Effectiveness (E2E) strategies.

CEO and President

2019 - 2024

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for high-risk cardiovascular patients. The company’s lead program is abelacimab (MAA868), an antibody exhibiting dual inhibition of coagulation Factor XI and its activated form XIa. Early clinical trials indicate abelacimab has the potential to attenuate pathological thrombosis with minimal impact on hemostasis, thereby preventing or treating a variety of thrombotic disorders with lowered bleeding risk. Abelacimab’s anticipated monthly dosing combined with the potential for greater effectiveness and lowered bleeding profile are expected to provide major advantages over existing standards of care and allow greater numbers of people to be treated.

Board Member

2017 - 2023

DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit.

Consultant

2017 - 2018

Consulting to Roivant on commercial go-to-market activities, including operating, launch, and access plans.

EVP, Head of Corporate Strategy and Customer Operations

2015 - 2017

Member of Executive Team that led Baxalta through spin-off from Baxter Healthcare and subsequent merger agreement with Shire to form a Top 20 biopharma company. Championed external product development model and led Baxalta Ventures and Vitesse Biologics, along with more traditional business development and licensing and M&A, to create a conduit between innovation and commercialization.

VP, Head of Emerging Therapies and Market Development, Bioscience

2012 - 2015

Built oncology franchise from the ground up with three in-licenses agreements and development of an internal commercial team. Architect of commercial infrastructure for $12 billion business built around the changing needs of multiple stakeholders – patients, physicians, providers, payers, and policymakers (P5) – establishing a comprehensive approach to the successful launch of new drugs.